Background Treatment with angiotensin converting enzyme inhibitors (ACEi) and
angiotensin receptor blockers (ARB) is increasingly used to reduce proteinuria and retard
the progression of chronic kidney disease (CKD). But some patients do not attain complete
resolution of proteinuria and might have higher aldosterone levels within few months of
treatment. The addition of aldosterone antagonists may be beneficial to these patients for
reduction of progression of renal damage. Objectives We evaluated the benefits and harms …